On October 6, 2026, McKesson Corporation announced a significant acquisition deal with Clayton, Dubilier & Rice (CD&R) to acquire Option Care Health, Inc. This move, valued at approximately $5.8 billion, is set to enhance McKesson's offerings in home and alternate site infusion services, reflecting a strategic effort to broaden patient access to complex therapies.
The acquisition will see CD&R take a majority ownership stake, while McKesson will hold a minority interest. Despite the change in ownership, Option Care Health will continue to operate independently under its existing management team.
Background
McKesson Corporation, a leading player in the wholesale-drugs industry (SIC: 5122), is listed on the New York Stock Exchange under the ticker symbol MCK. The company is known for its extensive distribution network and healthcare services, which aim to improve patient care and reduce costs. Recent filings include a Form 8-K on October 6, 2026, and several other forms leading up to this announcement.
What the Filing Says
The filing details a joint news release issued by McKesson, CD&R, and Option Care Health, outlining the terms of the acquisition. The release states, "We are pleased to have entered into this agreement, which provides immediate cash value for our stockholders." This sentiment was echoed by leaders from both McKesson and Option Care Health, emphasizing the strategic alignment and growth potential of the deal.
Impact
This acquisition is expected to have a considerable impact on various stakeholders, including shareholders of both McKesson and Option Care Health, as well as patients who will benefit from enhanced access to infusion therapies. The deal aligns with McKesson's long-term strategy to expand its footprint in specialty care and community-based healthcare services.
What's Next
The filing does not say what happens next, but the completion of the acquisition will likely involve regulatory approvals and further integration planning between the companies.